August 2026
M	T	W	T	F	S	S
	1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31

Pooja Choradia: 2026 Acute Pulmonary Embolism Clinical Guidelines

Pooja Choradia/Instagram

May 27, 2026, 13:54

Pooja Choradia: 2026 Acute Pulmonary Embolism Clinical Guidelines

Pooja Choradia, Critical Care Associate at P.D. Hinduja Hospital Khar, shared a post on LinkedIn:

“2026 AHA/ACC Pulmonary Embolism (PE) Clinical Categories

The 2026 guidelines transition from a binary risk model to a nuanced five-tiered (A–E) classification system, focusing on hemodynamic stability and physiological markers to guide patient management.

Category A: Asymptomatic PE

Defined as an incidental finding.
The patient is entirely asymptomatic.
Typically safe for emergency department discharge.

Category B: Symptomatic, Low-Severity

The patient is symptomatic but exhibits low clinical severity.
Based on low-risk clinical assessment tools (e.g., PESI/sPESI or Hestia criteria).
Early hospital discharge is generally recommended.

Category C: Elevated Severity

Characterized by an elevated clinical severity score (PESI III–V, sPESI ≥1, or Hestia ≥1).

C1: Normal right ventricular (RV) function and normal biomarkers.
C2: Abnormal RV function or ≥1 abnormal biomarker.
C3: Abnormal RV function AND ≥1 abnormal biomarker.

Category D: Incipient Cardiopulmonary Failure

The patient is showing signs of hemodynamic deterioration.

D1: Transient hypotension.
D2: Normotensive shock.

Category E: Established Cardiopulmonary Failure

Representing severe, persistent physiological failure.

E1: Persistent hypotension accompanied by cardiogenic shock.
E2: Refractory cardiogenic shock or cardiac arrest.

Management Highlights:

Physiological Focus: Management is driven by RV function and physiological stability rather than the anatomical clot burden.

Anticoagulation:

Direct Oral Anticoagulants (DOACs) are strongly prioritized for eligible patients.

Low-Molecular-Weight Heparin (LMWH) is preferred over Unfractionated Heparin (UFH) for initial therapy.

Extended treatment is recommended for patients with unprovoked PE or persistent risk factors.

Advanced Interventions: Therapies such as systemic thrombolysis, catheter-directed thrombolysis, mechanical thrombectomy, and surgical embolectomy are considered reasonable for Category E1 and selected Category D patients.

Systemic Care: Multidisciplinary Pulmonary Embolism Response Teams (PERTs) are recommended to streamline coordinated care.

Post-PE Surveillance: Formal screening for chronic thromboembolic pulmonary disease (CTEPD) and functional limitations is recommended for at least one year following the event.”

Pooja Choradia: 2026 Acute Pulmonary Embolism Clinical Guidelines